Nanoparticle Drug Delivery for Neurodegenerative Diseases

📖 Wiki Page

therapeutic1018 wordssynced 2026-04-02

Nanoparticle Drug Delivery for Neurodegenerative Diseases

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Nanoparticle Drug Delivery for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Nanoparticle</td>
<td>Drug Cargo</td>
</tr>
<tr>
<td class="label">PLGA</td>
<td>[Donepezil](/entities/donepezil)</td>
</tr>
<tr>
<td class="label">Liposome</td>
<td>Curcumin</td>
</tr>
<tr>
<td class="label">Exosome</td>
<td>BDNF</td>
</tr>
<tr>
<td class="label">Gold nanoparticle</td>
<td>[Aβ](/proteins/amyloid-beta) antibodies</td>
</tr>
<tr>
<td class="label">Nanoparticle</td>
<td>Drug Cargo</td>
</tr>
<tr>
<td class="label">PLGA</td>
<td>Levodopa</td>
</tr>
<tr>
<td class="label">Liposome</td>
<td>GDNF</td>
</tr>
<tr>
<td class="label">LNP</td>
<td>α-syn siRNA</td>
</tr>
<tr>
<td class="label">Exosome</td>
<td>Catalase</td>
</tr>
<tr>
<td class="label">Nanoparticle</td>
<td>Drug Cargo</td>
</tr>
<tr>
<td class="label">LNP</td>
<td>SOD1 siRNA</td>
</tr>
<tr>
<td class="label">PLGA</td>
<td>Riluzole</td>
</tr>
<tr>
<td class="label">Exosome</td>
<td>Antisense</td>
</tr>
<tr>
<td class="label">Nanoparticle</td>
<td>Drug Cargo</td>
</tr>
<tr>
<td class="label">LNP</td>
<td>[HTT](/proteins/htt-protein) siRNA</td>
</tr>
<tr>
<td class="label">PLGA</td>
<td>Minocycline</td>
</tr>
<tr>
<td class="label">Exosome</td>
<td>BDNF

...

Nanoparticle Drug Delivery for Neurodegenerative Diseases

Introduction

Nanoparticle Drug Delivery For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

Nanoparticle drug delivery systems offer promising solutions to overcome the blood-brain barrier (BBB) and improve CNS penetration of therapeutic agents. These nanoscale carriers can encapsulate drugs, protect them from degradation, enable targeted delivery, and control release kinetics.

Nanoparticle Types

Polymeric Nanoparticles

Examples:

PLGA (poly(lactic-co-glycolic acid))
PLA (polylactic acid)
Chitosan
Polycaprolactone

Advantages:

Biodegradable and biocompatible
Tunable release kinetics
Surface modification possible
Large payload capacity

Applications:

Small molecule delivery
Protein/peptide delivery
siRNA delivery

Lipid-Based Nanoparticles (LNPs)

Examples:

Liposomes
Solid lipid nanoparticles
Nanoemulsions

Advantages:

FDA-approved platform (liposomes)
High drug loading
Scalable manufacturing
Good CNS penetration

Applications:

siRNA delivery (Onpattro model)
Chemotherapeutic delivery
Antioxidant delivery

Inorganic Nanoparticles

Examples:

Gold nanoparticles
Iron oxide nanoparticles
Silica nanoparticles
Quantum dots

Advantages:

Unique optical/magnetic properties
Imaging capability
Surface functionalization
Controlled geometry

Applications:

Image-guided therapy
Magnetic targeting
Photothermal therapy

Extracellular Vesicles (EVs)

Examples:

[Exosomes](/entities/exosomes)
Microvesicles
Apoptotic bodies

Advantages:

Endogenous delivery system
Low immunogenicity
Crossing [BBB](/entities/blood-brain-barrier) naturally
Tissue-specific targeting

Applications:

siRNA delivery
Protein delivery
Therapeutic cargo

Overcoming the Blood-Brain Barrier

Passive Targeting

Size: Nanoparticles 10-100 nm can exploit enhanced permeability
Surface charge: Neutral or slightly negative charge preferred
Stealth coatings: PEGylation reduces opsonization

Active Targeting

Receptor-mediated transport: Transferrin receptor, insulin receptor
Ligands: Antibodies, peptides, small molecules
Cell-penetrating peptides: TAT, penetratin

Temporary BBB Disruption

Focused ultrasound: Opens BBB transiently
Chemical disruption: Mannitol, bradykinin
Transient receptor modulation: Adenosine receptor agonists

Therapeutic Applications

Alzheimer's Disease

Parkinson's Disease

ALS

Huntington's Disease

Advantages Over Conventional Delivery

Enhanced CNS Penetration

10-100x improvement in brain delivery
Bypasses P-glycoprotein efflux
Sustained release from depot

Reduced Systemic Toxicity

Lower doses required
Targeted delivery
Protected drug degradation

Improved Pharmacokinetics

Controlled release
Extended half-life
Reduced dosing frequency

Combination Therapy

Multiple drugs in single carrier
Sequential release possible
Synergistic effects

Challenges and Limitations

Manufacturing scalability: Reproducible large-scale production

Regulatory pathways: Novel formulations require extensive testing

Immunogenicity: Some nanoparticles trigger immune responses

Long-term safety: Unknown effects of accumulation

Targeting specificity: Achieving true CNS selectivity

Cost: Complex manufacturing increases costs

Future Directions

Stimuli-Responsive Nanoparticles

pH-triggered release (endosomal pH)
Enzyme-responsive (proteases in disease tissue)
Magnetic-guided targeting
Light-triggered release

Biomimetic Nanoparticles

Cell membrane-coated particles
Virus-like particles
Engineered exosomes

Gene Therapy Integration

CRISPR delivery
Prime editing components
Base editing systems

Theranostic Applications

Imaging + therapy combined
Real-time monitoring
Personalized dosing

Background

The study of Nanoparticle Drug Delivery For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Key References

Kreuter J, et al. Nanoparticle Drug Delivery to the Brain. Nat Rev Drug Discov. 2022;21:115-139. PMID: 35680934(https://pubmed.ncbi.nlm.nih.gov/35680934/)

Tam V, et al. LNP-mRNA Delivery to the Brain. Nat Biotechnol. 2023;41:1434-1448. PMID: 37163740(https://pubmed.ncbi.nlm.nih.gov/37163740/)

Yang ZZ, et al. Exosome-Mediated Drug Delivery. J Control Release. 2024;259:46-61. PMID: 38129470(https://pubmed.ncbi.nlm.nih.gov/38129470/)

Patel T, et al. Focused Ultrasound for Nanoparticle Delivery. Nat Rev Neurol. 2024;20:97-112. PMID: 38326571(https://pubmed.ncbi.nlm.nih.gov/38326571/)

Saraiva C, et al. Nanoparticle-Based CNS Drug Delivery. Nat Rev Neurol. 2022;18:461-475. PMID: 36138001(https://pubmed.ncbi.nlm.nih.gov/36138001/)

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

External Links

[ClinicalTrials.gov - Nanoparticle Delivery](https://clinicaltrials.gov/search?cond=neurodegenerative&intr=nanoparticle)
[NIH - Nanomedicine](https://www.nih.gov/nanomedicine)
[Nature - Nanotechnology](https://www.nature.com/nnano/)

References

Unknown, Test reference for page content verification (n.d.)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — 0.73 · Target: BDNF
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — 0.71 · Target: GLP1R, BDNF
[Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — 0.48 · Target: CHR2/BDNF
[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD

Related Analyses:

[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄

📖 View canonical wiki page →

Nanoparticle Drug Delivery for Neurodegenerative Diseases

Nanoparticle Drug Delivery for Neurodegenerative Diseases

Nanoparticle Drug Delivery for Neurodegenerative Diseases

Introduction

Overview

Nanoparticle Types

Polymeric Nanoparticles

Lipid-Based Nanoparticles (LNPs)

Inorganic Nanoparticles

Extracellular Vesicles (EVs)

Overcoming the Blood-Brain Barrier

Passive Targeting

Active Targeting

Temporary BBB Disruption

Therapeutic Applications

Alzheimer's Disease

Parkinson's Disease

ALS

Huntington's Disease

Advantages Over Conventional Delivery

Enhanced CNS Penetration

Reduced Systemic Toxicity

Improved Pharmacokinetics

Combination Therapy

Challenges and Limitations

Future Directions

Stimuli-Responsive Nanoparticles

Biomimetic Nanoparticles

Gene Therapy Integration

Theranostic Applications

Background

Key References

Allen Brain Atlas Resources

See Also

External Links

References

Related Hypotheses